The latest achievements of Renji Hospital Urology: Provide new ideas for treatment of rare renal cancer subtypes for the latest definition of the WHO

Recently, the Department of Urology, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, issued the results of the national multi -centered clinical research thesis: The progressive period of the immunohistocytic combined targeted therapy for patients with a defective renal cancer in the progress period is considerable. Research results were published online on June 15th in the Platinum journal "EUROPEAN UROLOGY (EUROPEAN UROLOGY" (IF: 20.096). The treatment of subtype patients provides new ideas.

FH defective kidney cancer is a rare pathological subtype of the World Health Organization (WHO) of the World Health Organization (WHO) in 2022. Its age of onset and strong invasion, early metastases, and the clinical diagnosis and treatment strategy urgently need to explore. For patients with FH defective renal cancer, the existing system treatment plan is limited and controversial. FH defective renal cancer is different from other types of kidney cancer in clinical manifestations and condition. This determines that special and comprehensive considerations are needed in terms of screening, diagnosis, treatment, and follow -up. Full management.

Led by Professor Xue Wei, deputy dean of Renji Hospital and director of the Department of Urology, Professor Zhang Jin, Department of Urology, led a national multi -center retrospective research. , Zhejiang University First Affiliated Hospital, including 15 clinical medical institutions, a total of 77 patients in the country, are the largest queue reported by the world to date, including 70 genetic smooth fibroids and kidney cell carcinoma with mutations of mutations in the FH gene embryo system mutations. (HLRCC) patients and 44 families.

The study found the unique genetic characteristics and clinical phenotypes of Chinese people. The results showed that the pathological combined genetic testing can significantly improve the accuracy of diagnosis. Immunomial combined targeted treatment schemes are the future direction. Members of patients' family members accept genetic consultation. On this basis, the urology is conducting a forward -looking marker exploration test (NCT05243173) in order to provide more powerful evidence for precise treatment.

Professor Xue Wei, Professor Zhang Jin, and Professor Huang Yiran of the Department of Urology of Renji Hospital communicated as the author of the paper. Dr. Xu Yunze, Dr. Kong Wen, and Dr. Cao Ming of the urology department are the first authors of the dissertation.

Renji Hospital's urological kidney tumor sub -professional team was led by Professor Huang Yiran in 2005. It was one of the earliest professional teams that began to focus on rare renal cancer, especially hereditary kidney cancer diagnosis and treatment, and the study of family departments. It has accumulated rich experience in the screening and diagnosis of rare renal cancer subtypes, course monitoring, surgery and recurrence surgery, and comprehensive treatment. In addition, the team emphasizes the concept of "special diseases and treatment" and individual chemical medical concepts. In the past three years, more than 1,000 renal tumor surgery has been completed each year. The surgical volume ranks first in Shanghai for 8 consecutive years. The research results of kidney tumors won a number of awards such as the second prize of Huaxia Science and Technology Progress in 2016, the first prize of the Ministry of Education Science and Technology Progress in 2016, and the first prize of the first prize of Shanghai Medical Science and Technology Progress.

Author: Tang Wenjia Kong Wen

Edit: Tang Wenjia

Editor in charge: Fan Liping

- END -